Catalytic Asymmetric β-Oxygen Elimination

A catalytic enantioselective β-O-elimination reaction is reported in the form of a zirconium-catalyzed asymmetric opening of meso-ketene acetals. Furthermore, a regiodivergent β-O-elimination is demonstrated. The reaction proceeds under mild conditions, at low catalyst loadings, and produces chiral monoprotected 1,2-diol building blocks in good yield and enantiomeric excess. The combination with a Mitsunobu reaction then gives access to all 1,2-diol stereoisomers and trans-1,2-aminoalcohols in high enantiomeric purity. A stereochemical analysis supported by DFT calculations reveals that a high selectivity in the hydrozirconation step is also important for achieving high enantioselectivity, although it does not constitute the asymmetric step. This insight is crucial for the future development of related asymmetric β-elimination reactions.

Enantiomeric purity deviations of radiolabelled amino acids obtained from chiral columns

Enantiomeric purity (EP) is an important value which denotes the relative percentage of the L-isomer with respect to the D-isomer. For 11C and 18F-labelled amino acid (AA) radiopharmaceutical (RP) production, EP represents a quality control parameter specified in European and national monographs for particular RPs. In most instances, EP value of greater then 90 or 95% (depending on AA type) is required as part of the quality control (QC) value of a RP following radiosynthesis. In common practice, two chromatographic columns are used for the EP determination of RPs: Crownpak CR(+) (Daicel), which contains a crown ether stationary phase or Chirobiotic T (Astec), which contains silica-bound glycoproteins as the stationary phase. The application of column Crownpak CR(+) requires that only perchloric acid solution (with pH 1–2) may be used, as the retention capability of the stationary phase is greatly reduced using organic solvents. This work intends to identify which chromatographic system is more accurate and reliable for EP determination as part of QC. We performed a series of parallel injections of the same batch of the widely used AA RPs [11C]MET and [18F]FET on the two aforementioned columns. The EP determination using column Crownpak CR(+) consistently provided a lower EP value compared to the Chirobiotic T column; the EP deviation between the respective columns was found to range from 2.4–4.0% for the same RP sample. Furthermore, the EP value was influenced by a sample’s dilution factor, e.g. the EP was observed to increase up to 1.5% when the radioactive sample had a fivefold dilution factor. This phenomenon was consistent for both Crownpak CR(+) and Chirobiotic T columns. Finally, a series of standard solutions of non-radioactive methionine with various ratios of L-and D-isomers was analyzed. The data obtained for non-radioactive methionine confirmed that column Crownpak CR(+) incorrectly provided a higher D-enantiomer concentration, whereas Chirobiotic T was found to provide a lower D-enantiomer concentration of the same sample. The deviation from the theoretical EP value was between 0.67 and 1.92%.

Microbial Synthesis of (S)- and (R)-Benzoin in Enantioselective Desymmetrization and Deracemization Catalyzed by Aureobasidium pullulans Included in the Blossom Protect™ Agent

In this study, we examined the Aureobasidium pullulans strains DSM 14940 and DSM 14941 included in the Blossom Protect™ agent to be used in the bioreduction reaction of a symmetrical dicarbonyl compound. Both chiral 2-hydroxy-1,2-diphenylethanone antipodes were obtained with a high enantiomeric purity. Mild conditions (phosphate buffer [pH 7.0, 7.2], 30 °C) were successfully employed in the synthesis of (S)-benzoin using two different methodologies: benzyl desymmetrization and rac-benzoin deracemization. Bioreduction carried out with higher reagent concentrations, lower pH values and prolonged reaction time, and in the presence of additives, enabled enrichment of the reaction mixture with (R)-benzoin. The described procedure is a potentially useful tool in the synthesis of chiral building blocks with a defined configuration in a simple and economical process with a lower environmental impact, enabling one-pot biotransformation.

Metathetic approach to new NORPHOS-related bisphosphanes: facile synthesis and application in asymmetric hydrogenation

A highly efficient synthesis of new chiral bisphosphanes derived from the renowned NORPHOS ligand is presented. The synthesis involves ring-opening metathesis of NORPHOS dioxide with an external olefin, followed by saturation of the new double bonds and adjustment of the oxidation level of phosphorus centers oxidation level. The synthesized bisphosphanes retain the configuration and enantiomeric purity of the starting NORPHOS. Their utility as ligands in asymmetric catalysis is exemplified using an open-NORPHOS ligand in some benchmark Rh-catalyzed hydrogenations of enamides where excellent chemical yields and enantiomeric purities of the products have been secured. The proposed protocol demonstrated the possibility of a straightforward synthesis of new chiral catalysts to be utilized in the asymmetric synthesis of pharmaceutically important compounds, such as amino acid derivatives.

From Natural Products to New Synthetic Small Molecules: A Journey through the World of Xanthones

This work reviews the contributions of the corresponding author (M.M.M.P.) and her research group to Medicinal Chemistry concerning the isolation from plant and marine sources of xanthone derivatives as well as their synthesis, biological/pharmacological activities, formulation and analytical applications. Although her group activity has been spread over several chemical families with relevance in Medicinal Chemistry, the main focus of the investigation and research has been in the xanthone family. Xanthone derivatives have a variety of activities with great potential for therapeutic applications due to their versatile framework. The group has contributed with several libraries of xanthones derivatives, with a variety of activities such as antitumor, anticoagulant, antiplatelet, anti-inflammatory, antimalarial, antimicrobial, hepatoprotective, antioxidant, and multidrug resistance reversal effects. Besides therapeutic applications, our group has also developed xanthone derivatives with analytical applications as chiral selectors for liquid chromatography and for maritime application as antifouling agents for marine paints. Chemically, it has been challenging to afford green chemistry methods and achieve enantiomeric purity of chiral derivatives. In this review, the structures of the most significant compounds will be presented.

Neutral pH Formulation for 6-[18F]fluoro-ʟ-DOPA With High Radiochemical Stability

6-[18F]Fluoro-L-DOPA(FDOPA) has always been generally produced under strong acidic conditions, i.e. as an injectable solution of pH 2~3, due to its low stability at a higher or neutral pH. This necessitates the pre-treatment neutralization of this agent with an injectable NaHCO3 solution. We have developed a neutral pH formulation for [18F]FDOPA using ethanol (EtOH) and phosphate buffer to overcome the radioactive and enantiomeric stability problems at a higher pH. Upon [18F]FDOPA generation by nucleophilic substitution methods, we investigated its radiochemical and enantiomeric purity in accordance with the various pH after 6 hours. After EtOH and three kinds of buffer were added, we further examined this purity at pH 6 ~ 7 after 6 hours. The ascorbic acid did not stabilize the radiochemical purity at the higher pH. A 5% EtOH and PBS buffer matrix produced the best stability for radiochemical and enantiomeric purity at pH 6.5 at the 6 hour time point. This combination maintained a > 95% radiochemical and enantiomeric purity at 6 hours after EOS (end of synthesis). Our new formulation for [18F]FDOPA thus showed a high stability at neutral pH and satisfied QC requirements which was listed in European Pharmacopeia. It has also been approved by the Korean Ministry of Food and Drug Safety.